Evidence
Nat Metab. 2023 Jul 6. doi: 10.1038/s42255-023-00834-7. Online ahead of print.
ABSTRACT
Although multiple populations of macrophages have been described in the human liver, their function and turnover in patients with obesity at high risk of developing non-alcoholic fatty liver disease (NAFLD) and cirrhosis are currently unknown. Herein, we identify a specific human population of resident liver myeloid cells that protects against the metabolic impairment associated with obesity. By studying the turnover of liver myeloid cells in individuals undergoing liver transplantation, we find that liver myeloid cell turnover differs between humans and mice. Using single-cell techniques and flow cytometry, we determine that the proportion of the protective resident liver myeloid cells, denoted liver myeloid cells 2 (LM2), decreases during obesity. Functional validation approaches using human 2D and 3D cultures reveal that the presence of LM2 ameliorates the oxidative stress associated with obese conditions. Our study indicates that resident myeloid cells could be a therapeutic target to decrease the oxidative stress associated with NAFLD.
PMID:37414931 | DOI:10.1038/s42255-023-00834-7
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Human resident liver myeloid cells protect against metabolic stress in obesity
🌐 90 Days
VR Related Evidence Matrix
- Spatial genomics: mapping human steatotic liver disease
- The niche matters: origin, function and fate of CNS-associated macrophages during health and disease
- Concomitant NAFLD facilitates liver metastases and PD-1-refractory by recruiting MDSCs via CXCL5/CXCR2 in colorectal cancer
- Kupffer cell diversity maintains liver function in alcohol-associated liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Generation and characterization of mature hepatocyte organoids for liver metabolic studies
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Occult liver disease: a multinational perspective
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- COVID-19 in Individuals with Chronic Liver Diseases
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Inflammatory liver diseases and susceptibility to sepsis
- The GPR40 novel agonist SZZ15-11 improves non-alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet-induced obese mice
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- The gut-liver axis in fatty liver disease: role played by natural products
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Interleukins in liver disease treatment
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation
- Accumulation of Non-Pathological Liver Fat Is Associated with the Loss of Glyoxalase I Activity in Humans
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Punicic acid ameliorates obesity-related hyperlipidemia and fatty liver in mice via regulation of intestinal flora and lipopolysaccharide-related signaling pathways
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Amelioration of NAFLD by sleeve gastrectomy-triggered hepatocyte regeneration in mice - experimental research
- The transcription factor ZNF469 regulates collagen production in liver fibrosis
- Association of sex-specific body mass index and waist circumference trajectories with non-alcoholic fatty liver disease incidence based on growth mixture modeling
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice
- Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery
Evidence Blueprint
Human resident liver myeloid cells protect against metabolic stress in obesity
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Human resident liver myeloid cells protect against metabolic stress in obesity
🌐 365 Days
VR Related Evidence Matrix
- Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling
- Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice
- Multiomic spatial landscape of innate immune cells at human central nervous system borders
- Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions
- Spatial genomics: mapping human steatotic liver disease
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- The niche matters: origin, function and fate of CNS-associated macrophages during health and disease
- Novel phenotypical and functional sub-classification of liver macrophages highlights changes in population dynamics in experimental mouse models
- Tracer-Based Metabolic Analysis by NMR in Intact Perfused Human Liver Tissue
- NCOA5 haploinsufficiency in myeloid-lineage cells sufficiently causes non-alcoholic steatohepatitis and hepatocellular carcinoma
- Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Concomitant NAFLD facilitates liver metastases and PD-1-refractory by recruiting MDSCs via CXCL5/CXCR2 in colorectal cancer
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Liver-derived extracellular vesicles improve whole-body glycaemic control via inter-organ communication
- Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease
- Macrophages and the development and progression of non-alcoholic fatty liver disease
- Liver health and the interplay between obesity, alcohol and bariatric surgery
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- TIME-RESTRICTED FEEDING COMBINED WITH RESISTANCE EXERCISE TRAINING PREVENTS OBESITY AND IMPROVES LIPID METABOLISM IN THE LIVER OF MICE FED A HIGH-FAT DIET
- Kupffer cell diversity maintains liver function in alcohol-associated liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD
- Peripheral and central macrophages in obesity
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Liver sinusoidal endothelial transcription factors in metabolic homeostasis and disease
- Fatty liver disease's renaming impacts on drug clinical trials
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- How myeloid cells shape experimental autoimmune encephalomyelitis: at the crossroads of outside-in immunity
- Mononuclear myeloid-derived suppressor cells expansion is associated with progression of liver failure in patients with acute decompensation of cirrhosis
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Modelling porcine NAFLD by deletion of leptin and defining the role of AMPK in hepatic fibrosis
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Pregnane X receptor activation remodels glucose metabolism to promote NAFLD development in obese mice
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Human APOE4 Protects High-Fat and High-Sucrose Diet Fed Targeted Replacement Mice against Fatty Liver Disease Compared to APOE3
- Corrected and republished from: Metabolic associated liver disease
- Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives
- Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver
- Generation and characterization of mature hepatocyte organoids for liver metabolic studies
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Therapeutic potential of oleanolic acid in liver diseases
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
- Overexpression of lncRNA HEM2M alleviates liver injury in mice with non-alcoholic fatty liver disease
- Ablation of dual specificity phosphatase 6 protects against non-alcoholic fatty liver disease via CYP4A and MAPK
- Vitamin D/Vitamin D receptor pathway in nonalcoholic fatty liver disease
- Review of paediatric obesity and non-alcoholic fatty liver disease-A focus on emerging non-pharmacologic treatment strategies
- p53R245W mutation fuels cancer initiation and metastases in NASH-driven liver tumorigenesis
- IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity and associated with liver stiffness and fibrosis in fatty liver disease
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12